Pharmafile Logo

Almirall’s Klisyri receives positive CHMP opinion to extend skin treatment area for actinic keratosis

Actinic keratosis is a chronic skin disease and one of the most common diagnoses in dermatology practices in Europe
- PMLiVE

Almirall’s Klisyri (tirbanibulin) has received a positive opinion recommending the regulatory approval of an extension of indication for the 10mg/g ointment from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

The label extension expands the treatment field to up to four times the surface area of the face or scalp in adults with actinic keratosis (AK). This represents an important step forward in the management of AK in Europe, allowing dermatologists to treat larger fields of cancerisation while offering patients the same short five-day topical treatment regimen, consistent efficacy and favourable tolerability established in the original pivotal trials.

AK is a chronic skin disease and one of the most common diagnoses in dermatology practices in Europe, with an estimated prevalence of around 14%. As lesions may progress to invasive squamous cell carcinoma (SCC), ongoing management is important. Short, convenient and well-tolerated treatments are particularly relevant, helping to reduce the treatment burden for patients and supporting adherence to ongoing disease management.

Karl Ziegelbauer, Chief Scientific Officer at Almirall, said: “Actinic keratosis rarely occurs as isolated lesions, and dermatologists in Europe need effective therapeutic options to treat larger affected skin areas. Expanding the treatment area up to 100 cm² would provide physicians with greater clinical flexibility to address widespread field cancerisation. The short five-day duration of treatment, combined with proven efficacy and a favourable safety and tolerability profile, reinforces tirbanibulin as an important therapeutic option for AK in the EU.”

In June 2024, the US FDA approved Almirall’s supplemental New Drug Application (sNDA) to expand its use up to 100cm² in the US. The positive opinion is supported by the TirbAKare phase 3 study, which shows clinically and statistically significant percent reduction in AK lesions, with a consistent safety profile and local tolerability, for tirbanibulin in treatment areas up to 100 cm².

PMGroup
19th November 2026
Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links